Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Adolescent
Adult
Aged
Cohort Studies
Female
Ferritins
/ analysis
Graft vs Host Disease
/ blood
Hematologic Neoplasms
/ blood
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Recurrence
Retrospective Studies
Survival Analysis
Time Factors
Transplantation, Homologous
/ adverse effects
Treatment Outcome
Young Adult
Biomarker
Ferritin
Graft-versus-host disease
Mortality
Prognosis
Prognostic marker
Survival
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
18
10
2019
accepted:
30
11
2020
pubmed:
9
1
2021
medline:
6
3
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (HCT) is associated with significant morbidity and mortality. Elevated pre-transplant ferritin level (ferritin
Identifiants
pubmed: 33415423
doi: 10.1007/s00277-020-04363-1
pii: 10.1007/s00277-020-04363-1
doi:
Substances chimiques
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-798Références
Paczesny S (2018) Biomarkers for posttransplantation outcomes. Blood 131:2193–2204. https://doi.org/10.1182/blood-2018-02-791509
doi: 10.1182/blood-2018-02-791509
pubmed: 29622549
pmcid: 5958654
Yan, Z. et al. Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Medicine (United States) (2018). doi: https://doi.org/10.1097/MD.0000000000010310
Bazuave GN, Buser A, Gerull S, Tichelli A, Stern M (2012) Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant 47:60–64. https://doi.org/10.1038/bmt.2011.13
doi: 10.1038/bmt.2011.13
pubmed: 21399668
Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377:2565–2579
doi: 10.1056/NEJMra1703472
Pond G, Lipton J, Messner H (2006) Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transpl 12:422–429
doi: 10.1016/j.bbmt.2005.11.518
Gupta, V., Daly, A., Lipton, J. & Al., E. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transpl. 11, 764–72 (2005)
Kiss, T., Panzarella, T., Messner, H. & Al., E. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transpl. 31, 73–8 (2003)
Messner H (2002) Long-term outcome of allogeneic transplants in acute myeloid leukemia. Leukemia 16:751–752
doi: 10.1038/sj.leu.2402463
Kim, D., Messner, H., Minden, M. & Al., E. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl. Infect Dis. 10, 90–8 (2008)
Kim, D., Jamal, N., Saragosa, R. & Al., E. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transpl. 13, 1233–43 (2007)
Armand, P., Kim, H., Logan, B. & Al., E. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664–3671 (2014)
Przepiorka, D., Weisdorf, D., Martin, P. & Al., E. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl. 15, 825–8 (1995)
Filipovich & Al., E. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transpl. 11, 945–956 (2005)
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl 48:452–458
doi: 10.1038/bmt.2012.244
Meyer, S., O’Meara, A., Buser, A. & Al., E. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 19, 440–444 (2013)
Goldberg, S., Elmann, M., Kaminetzky, M. & Al., E. One-year post-transplant serum ferritin level is a predictor of long-term survival following allogeneic transplantation. Blood 116, 3453 (2010)
Tachibana, T., Tanaka, M., Numata, A. & Al., E. Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients. Leuk. Lymphoma 55, 1350–1356 (2014)
M., N. et al. Prognostic value and clinical implication of serum ferritin levels following allogeneic hematopoietic cell transplantation. Acta Haematol. (2015). doi: https://doi.org/10.1159/000365779
Brissot E, Savani BN, Mohty M (2012) Management of high ferritin in long-term survivors after hematopoietic stem cell transplantation. Semin Hematol 49:35–42
doi: 10.1053/j.seminhematol.2011.10.003
Kontoghiorghes GJ (2020) How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation? Expert Rev Hematol 13:299–302. https://doi.org/10.1080/17474086.2020.1719359
doi: 10.1080/17474086.2020.1719359
pubmed: 32037922
Tachibana T et al (2018) Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Int J Hematol 107:578–585. https://doi.org/10.1007/s12185-017-2396-9
doi: 10.1007/s12185-017-2396-9
pubmed: 29305770
Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB (2017) One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer 64:188–196. https://doi.org/10.1002/pbc.26213
doi: 10.1002/pbc.26213
pubmed: 27576370
Sucak GT, Yegin ZA, Özkurt ZN, Akı ŞZ, Karakan T, Akyol G (2008) The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42:461–467. https://doi.org/10.1038/bmt.2008.193
doi: 10.1038/bmt.2008.193
pubmed: 18604240
Tachibana, T., Takana, M., Motohashi, K. & Al., E. Clinical significance of serum ferritin compared to liver iron content, measured using magnetic resonance imaging, after allogeneic hematopoietic cell transplantation. J. Hematop. Cell Transplant. 4, 47–51 (2015)
Mahindra A, Bolwell B (2009) Sobecks, R. & Al., E. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft vs host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Brit J Haematol 146:310–316
doi: 10.1111/j.1365-2141.2009.07774.x
Sakamoto S, Kawabata H (2013) Kanda, J. & Al., E. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol 97:109–116
doi: 10.1007/s12185-012-1229-0
Tanaka, M., Kanamori, H., Matsumoto, K. & Al., E. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy. Bone Marrow Transpl. 50, 727–733 (2015)
Wingard, J., Piantadosi, S., Vogelsang, G. & Al., E. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74, 1428–1435 (1989)
Stewart, B., Storer, B., Storek, J. & Al., E. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 104, 3501–3506 (2004)
Sullivan, K., Witherspoon, R., Storb, R. & Al., E. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 72, 546–554 (1988)
Akpek G, Zahurak M (2001) Piantadosi, S. & Al., E. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97:1219–1226
doi: 10.1182/blood.V97.5.1219
Arora, M., Burns, L., Davies, S. & Al., E. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transpl. 9, 38–45 (2003)
Kuzmina Z, Eder S (2012) Bohm, A. & Al., E. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26:746–756
doi: 10.1038/leu.2011.257
Arora, M., Klein, J., Weisdorf, D. & Al., E. Chronic GVHD risk score: a center for International Blood and Marrow Transplant Research analysis. Blood 117, 6714–6720 (2011)
Inamoto, Y., Kim, D., Storer, B. & Al., E. Application of CIBMTR risk score to NIH chronic GVHD at individual centers. Blood 123, 453–455 (2014)
Arora M, Hemmer M, Ahn K et al (2015) Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transpl. 2:640–645
doi: 10.1016/j.bbmt.2014.10.022
Moon, J., Hamad, N., Sohn, S. & Al., E. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. Ann. Hematol. 96, 805–815 (2017)